Recurrent angina in patients who underwent percutaneous coronary intervention is defined as recurrence of chest pain or chest discomfort. Careful assessment is recommended to differentiate between non-cardiac and cardiac causes. In the case of the latter, recurrent angina occurrence can be related to structural (‘stretch pain’, in-stent restenosis, in-stent thrombosis, incomplete revascularization, progression of coronary atherosclerosis) or functional (coronary micro-vascular dysfunction, epicardial coronary spasm) causes. Even though a complete diagnostic algorithm has not been validated, ECG exercise testing, stress imaging and invasive assessment of coronary blood flow and coronary vaso-motion (i.e. coronary flow reserve, provocation testing for coronary spasm) may be required. When repeated coronary revascularization is not indicated, therapeutic approaches should aim at targeting the underlying mechanism for the patient’s symptoms using a variety of drugs currently available such as beta-blockers, calcium-channel blockers, ivabradine or ranolazine.
KoDTTuJVSamadashviliZ. Temporal trends in the use of percutaneous coronary intervention and coronary artery bypass surgery in New York State and Ontario. Circulation2010; 121: 2635–2644.
2.
AbramsJ. Chronic stable angina. N Engl J Med2005; 352: 2524–2552.
3.
PocockSJHendersonRASeedP. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation1996; 94: 135–142.
4.
WijnsWKolhPDanchinN. Guidelines on myocardial revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J2010; 31: 2501–2555.
5.
BodenWEO’rourkeRATeoKK.; COURAGE trial coprincipal investigators and study coordinators. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE trial). Am Heart J2006; 151: 1173–1179.
6.
RamsdaleDRRaoAAsgharO. Late outcomes after drug-eluting stent implantation in ‘real-world’ clinical practice. J Invasive Cardiol2008; 20: 493–500.
7.
KirwanBALubsenJPoole-WilsonPA; ACTION investigators. Treatment of angina pectoris: Associations with symptom severity. Int J Cardiol2005; 98: 299–306.
8.
WeintraubWSSpertusJAKolmP.; Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med2008; 359: 677–687.
9.
PepineCJAbramsJMarksRG.; TIDES investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol1994; 74: 226–231.
10.
RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet1997; 350: 461–468.
11.
HendersonRAPocockSJClaytonTC.; for the Second Randomised Intervention Treatment of Angina (RITA-2) trial participants. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol2003; 42: 1161–1170.
12.
KimMCKiniASharmaSK. Refractory angina pectoris: Mechanisms and therapeutic options. J Am Coll Cardiol2002; 39: 923–934.
13.
LemosPAHoyeASerruysPW. Recurrent angina after revascularization: an emerging problem for the clinician. Coron Artery Dis2004; 15(Suppl. 1): S11–S15.
14.
ShahBRCowperPAO’BrienSM. Patterns of cardiac stress testing after revascularization in community practice. J Am Coll Cardiol2010; 56: 1328–1334.
15.
HolubkovRLaskeyWKHavilandA.; NHLBI Dynamic Registry. Registry Investigators. Angina one year after percutaneous coronary intervention: A report from the NHLBI Dynamic Registry. Am Heart J2002; 144: 826–833.
16.
SerruysPWUngerFSousaJE.; Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med2001; 344: 1117–1124.
17.
EisenbergMJOkrainecKLefkovitsJ.; for the ROSETTA Investigators. Medical therapy in patients undergoing percutaneous coronary intervention: Results from the ROSETTA registry. Can J Cardiol2003; 19: 1009–1015.
18.
JeremiasAKutscherSHaudeM. Nonischemic chest pain induced by coronary interventions: A prospective study comparing coronary angioplasty and stent implantation. Circulation1998; 98: 2656–2658.
19.
JoelsonJMMostASWilliamsDO. Angiographic findings when chest pain recurs after successful percutaneous transluminal coronary angioplasty. Am J Cardiol1987; 60: 792–795.
20.
Al SuwaidiJHolmesDRSalamAM. Impact of coronary artery stents on mortality and non-fatal myocardial infarction: Meta-analysis of randomized trial comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J2004; 147: 815–822.
21.
IndolfiCPaviaMAngelilloIF. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol2005; 95: 1146–1152.
CorbettSJCosgraveJMelziG. Pattern of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus and paclitaxel-eluting. Eur Heart J2006; 27: 2330–2337.
24.
CosgraveJMelziGBiondi-ZoccaiGGL. Drug-eluting stent restenosis: The pattern predicts the outcome. J Am Coll Cardiol2006; 47: 2399–2407.
25.
OngATLMcFaddenEPRegarE. Late angiographic stent thrombosis (LAST events with drug eluting stents). J Am Coll Cardiol2005; 45: 2088–2093.
26.
OngATLHoyeAAokiJ. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol2005; 45: 947–953.
27.
LemesleGDelhayeCBonelloL. Stent thrombosis in 2008: Definition, predictors, prognosis and treatment. Arch Cardiovasc Dis2008; 101: 769–767.
28.
IakovouISchmidtTBonizzoniE. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stent. JAMA2005; 293: 2126–2130.
29.
JonerMFinnAWFarbA. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. J Am Coll Cardiol2006; 48: 193–202.
30.
SerruysPWMoriceMCKappeteinAP.; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med2009; 360: 961–972.
31.
Van den BrandMJRensingBJMorelMA.; on behalf of the ARTS Investigators. The effect of the completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol2002; 39: 559–564.
32.
LoutfiMMulvihillNTBoccalatteM. Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients. Catheter Cardiovasc Interv2003; 58: 451–454.
33.
The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med1996; 335: 217–225.
34.
el-TamimiHDaviesGJSritaraP. Inappropriate constriction of small coronary vessels as a possible cause of a positive exercise test early after successful coronary angioplasty. Circulation1991; 84: 2307–2312.
35.
ItoSNakasukaKMorimotoK. Angiographic and clinical characteristics of patients with acetylcholine-induced coronary vasospasm on follow-up coronary angiography following drug-eluting stent implantation. J Invasive Cardiol2011; 23: 57–64.
36.
MonninkSHTioRAVeegerNJ. Exercise-induced ischemia after successful percutaneous coronary intervention is related to distal coronary endothelial dysfunction. J Invest Med2003; 51: 221–226.
37.
PijlsNHVan SchaardenburghPManoharanG. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol2007; 49: 2105–2111.
38.
ToninoPADe BruyneBPijlsNH., for the FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009; 360:213–224
39.
EisenbergMJWouKNguyenH. Lack of benefit for routine functional testing early after coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry. J Invasive Cardiol. 2006; 18:147–52.
40.
MakKHEinsenbergMJTsangJ.; for ROSETTA Investigators. Clinical impact of functional testing strategy among stented and non-stented patients: Insights from the ROSETTA registry. Int J Cardiol2004; 95: 321–327.
41.
EisenbergMJBlankenshipJCHuynhT.; for the ADORE Investigators. Evaluation of routine functional testing after percutaneous coronary intervention. Am J Cardiol2004; 93: 744–747.
42.
LevineGNChodosAPLoscalzoJ. Restenosis following coronary angioplasty: Clinical presentations and therapeutic options. Clin Cardiol1995; 18: 693–703.
43.
DaimonMWatanabeHYamagishiH. Physiologic assessment of coronary artery stenosis by coronary flow reserve measurements with transthoracic Doppler echocardiography: Comparison with exercise thallium-201 single photon emission computer tomography. J Am Coll Cardiol2001; 37: 1310–1315.
44.
RathoreSTerashimaMKatohO. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: Contemporary practice in real world patients. EuroIntervention2009; 5: 349–354.
45.
CutlipDEChauhanMSBaimDS. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol2002; 40: 2082–2089.
46.
UrenNGMarracciniPGistriR. Altered coronary vasodilator reserve and metabolism in myocardium subtended by normal arteries in patients with coronary artery disease. J Am Coll Cardiol1993; 22: 650–658.
47.
GibbonsRJAbramsJChatterjeeK. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol2003; 41: 159–168.
48.
FoxKGarciaMAArdissinoD.; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J2006; 27: 1341–1381.
49.
ThérouxPMarpoleDGBourassaMG. Exercise stress testing in the post-myocardial infarction patient. Am J Cardiol1983; 52: 664–667.
50.
BabapulleMNDiodatiJGBlankenshipJC. Utility of routine exercise treadmill testing early after percutaneous coronary intervention. BMC Cardiovasc Disord2007; 7: 12.
51.
DoriGDenekampYFishmanS. Exercise stress testing, myocardial perfusion imaging and stress echocardiography for detecting restenosis after successful percutaneous transluminal coronary angioplasty: A review of performance. J Intern Med2003; 253: 253–262.
52.
WongDTLeungMCDasR. Diagnostic accuracy of adenosine stress cardiovascular magnetic resonance following acute ST-segment elevation myocardial infarction post primary angioplasty. J Cardiovasc Magn Reson2011; 13: 62.
53.
BernhardtPSpiessJLevensonB. Combined assessment of myocardial perfusion and late gadolinium enhancement in patients after percutaneous coronary intervention or bypass grafts: A multicenter study of an integrated cardiovascular magnetic resonance protocol. JACC Cardiovasc Imaging2009; 2: 1292–1300.
54.
KernMJLermanABechJ-W. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory. Circulation2006; 114: 1321–1341.
55.
OngPAthanasiadisABorgulyaG. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol2012; 59: 655–662.
56.
PetrettaMCostanzoPCuocoloA. Imaging techniques for the assessment of coronary flow reserve. Eur Cardiol2008; 4: 37–40.
57.
L’AbbateASambucetiGHaunsoS. Methods for evaluating coronary microvasculature in humans. Eur Heart J1999; 20: 1300–1313.
58.
MeimounPTribouilloyC. Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world. Eur J Echocardiogr2008; 9: 449–457.
59.
GouldKLKirkeeideRLBuchiM. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol1990; 15: 459–474.
60.
MillerDDDonohueTJYounisLT. Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. Circulation1994; 89: 2150–2160.
61.
HozumiTYoshidaKOgataY. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation1998; 97: 1557–1562.
62.
CaiatiCMontaldoCZeddaN. New non-invasive method for coronary flow reserve assessment: Contrast-enhanced transthoracic second harmonic echo Doppler. Circulation1999; 99: 771–778.
63.
PepineCJAndersonRDSharafBL. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol2010; 55: 2825–2832.
64.
PetrettaMSoricelliAStortoG. Assessment of coronary flow reserve using single photon emission computed tomography with technetium 99m-labeled tracers. J Nucl Cardiol2008; 15: 456–465.
65.
StortoGCirilloPVicarioML. Estimation of coronary flow reserve by Tc-99m sestamibi imaging in patients with coronary artery disease: Comparison with the results of intracoronary Doppler technique. J Nucl Cardiol2004; 11: 682–688.
66.
BergmannSRHerreroPMarkhamJ. Non-invasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol1989; 14: 639–652.
67.
MasudaDNoharaRTamakiN. Evaluation of coronary blood flow reserve by 13N-NH3 positron emission computed tomography (PET) with dipyridamole in the treatment of hypertension with the ACE inhibitor (Cilazapril). Ann Nucl Med2000; 14: 353–360.
68.
RieberJHuberAErhardI. Cardiac magnetic resonance perfusion imaging for the functional assessment of coronary artery disease: a comparison with coronary angiography and fractional flow reserve. Eur Heart J2006; 27: 1465–1471.
69.
JaffeRDickAStraussBH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: A systematic approach. JACC Cardiovasc Interv2010; 3: 695–704.
70.
CutrnJCPerrelliMGCavalieriB. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radic Biol Med2002; 33: 1200–1208.
71.
BekkersSCYazdaniSKVirmaniR. Microvascular obstruction: Underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol2010; 55: 1649–1660.
72.
FayadZAFusterVNikolaouK. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: Current and potential future concepts. Circulation2002; 106: 2026–2034.
73.
GasparTHalonDALewisBS. Diagnosis of coronary in-stent restenosis with multidetector row spiral computed tomography. J Am Coll Cardiol2005; 46: 1573–1579.
FrakerTDFihnSD. 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. Circulation2007; 116: 20762-20772.
78.
JacksonJDMuhlesteinJBBunchTJ.; Intermountain Heart Collaborative Study Group. Beta-blockers reduce the incidence of clinical restenosis: Prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J2003; 145: 875-881.
79.
VersaciFGaspardoneATomaiF. Chest pain after coronary artery stent placement. Am J Cardiol2002; 89: 500–504.
80.
KakuBHoninIKHoritaY. The incidence of stent-edge spasm after stent implantation in patient with or without vasospastic angina pectoris. Int Heart J2005; 46: 23–33.
81.
CortiRFusterV. Should standard medical therapy for angina include a statin?Clin Cardiol2004; 27: 547–545.
82.
NissenSENichollsSJSipahiI.; for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA2006; 295: 1556–1565.
83.
ColinPGhalehBMonnetX. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol2003; 284: H676–H682.
FoxKFordIStegPG.; on behalf of the BEAUTIFUL investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J2009; 30: 2337–2345.
86.
TardifJCPonikowskiPKahanT; ASSOCIATE study investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta blocker therapy: A 4 month, randomized, placebo-controlled trial. Eur Heart J2009; 30: 540–548.
87.
KösterRKaehlerJMeinertzT; REDUCTION Study Group. Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION study. Am Heart J2009; 158: e51–e57.
88.
BorerJSFoxKJaillonP.; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation2003; 107: 817–823.
89.
TardifJCFordITenderaM.; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J2005; 26: 2529–2536.
90.
RuzylloWTenderaMFordI. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs2007; 67: 393–405.
91.
RuzylloWSwedHSadowskiZ. Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study. Curr Med Res Opin2004; 20: 1447–1454.
ChaitmanBRPepineCJParkerJO.; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA2004; 291: 309–316.
94.
StonePHGratsianskyNABlokhinA.; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol2006; 48: 566–575.
95.
WilsonSRSciricaBMBraunwaldE. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double blind, placebo controlled MERLIN-TIMI (Metabolic efficiency with Ranolazine for less ischemia in non ST-segment Elevation acute Coronary Syndrome) 36 TRIAL. J Am Coll Cardiol2009; 53: 1510–1516.
96.
RousseauMFPouleurHCoccoG. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol2005; 95: 311–316.
97.
ArnoldSVMorrowDAWangK.; MERLIN-TIMI 36 Investigators. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: Results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes2008; 1: 107–115.
98.
MatsuoHWatanabeSSegawaT. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Eur Heart J2003; 24: 1296–1130.
99.
IONA study group. Effect of Nicorandil on coronary events in patients with stable angina. The Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet2002; 359: 1269–1275.
100.
HambrechtRWaltherCMobius-WinklerS. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease. Circulation2004; 109: 1371–1378.
101.
CreaFLanzaGA. Angina pectoris and normal coronary arteries: Cardiac syndrome X. Heart2004; 90: 457–463.
102.
DougenisDKellyPJBrownAH. Late survival and predictors of recurrent angina after coronary artery reoperation. Thorac Cardiovasc Surg1997; 45: 114–118.
103.
KastratiAMehilliJvon BekerathN.; for ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA2005; 293: 165–171.
104.
SinghIMFilbySJEl SakrF. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter Cardiovasc Interv2010; 76: 257–262.
105.
IofinaERadkePWSkurzewskiP. Superiority of sirolimus eluting stent compared with intracoronary beta radiation for treatment of in-stent restenosis: A matched comparison. Heart2005; 91: 1584-1589.
106.
FitzgibbonGMKafkaHPLeachAJ. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol1996; 28: 616–626.
107.
SavageMDouglasJFischmanD. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med1997; 337: 740–747.
108.
StoneGWRogersCHermillerJ.; on behalf of the FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation2003; 108: 548–553.
109.
VermeerschPAgostoniP. Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents?J Interv Cardiol2005; 18: 467–473.
110.
EllisSGBrenerSJDelucaS. Late myocardial ischaemic events after saphenous vein graft intervention–importance of initially ‘nonsignificant’ vein graft lesions. Am J Cardiol1997; 79: 1460–1464.
111.
GowdaRMKhanIAPunukolluG. Treatment of refractory angina pectoris. Int J Cardiol2005; 101: 1–7.
EltchaninoffHCarlotRTronC. Analysis of nonintervention strategy for in-stent restenosis in Pauci- or asymptomatic patients. Am J Cardiol2004; 93: 1038–1040.
114.
KuchulakantiPKChuWWTorgusonR. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation2006; 113: 1108-1113.
115.
CutlipDEBaimDSHoKK. Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation2001; 103: 1967–1971.
116.
LemesleGSudreAModineT. High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis. Catheter Cardiovasc Interv2008; 72: 470–478.
117.
TanKHSulkeNTaubN. Predictors of angiographic findings when chest pain recurs after successful coronary angioplasty. Eur Heart J1995; 16: 1593–1602.
118.
AldermanELKipKEWhitlowPL.; Bypass Angioplasty Revascularization Investigation. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol2004; 44: 766–774.
119.
FaxonDPGhalilliKJacobsAK. The degree of revascularization and outcome after multivessel coronary angioplasty. Am Heart J1992; 123: 854–859.
120.
BellMRBaileyKRReederGS. Percutaneous transluminal angioplasty in patients with multivessel coronary disease: How important is complete revascularization for cardiac event-free survival?J Am Coll Cardiol1990; 16: 553–562.
121.
SamsonMMeesterHJDe FeyterPJ. Successful multiple segment coronary angioplasty: Effect of completeness of revascularization in single-vessel multilesions and multivessels. Am Heart J1990; 120: 1–12.
122.
BrittenMBZeiherAMSchächingerV. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Artery Dis2004; 15: 259–264.
123.
BologneseLCarrabbaNParodiG. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation2004; 109: 1121–1126.
124.
KatohDMizunoYHaradaE. High incidence of provoked coronary spasm in the presence of a stent after myocardial infarction: Therapeutic and prognostic implications. Coron Artery Dis2012; 23: 141–145.
125.
SchindlerTHHornigBBuserPT. Prognostic value of abnormal vasoreactivity of epicardial coronary arteries to sympathetic stimulation in patients with normal coronary angiograms. Arterioscler Thromb Vasc Biol2003; 23: 495–501.
